Infinity Pharmaceuticals is “focused on bringing significantly better treatments to cancer patients” and using data-driven methods to achieve those results. The firm focuses on integrity, empathy and communication.
Infinity Pharmaceuticals (NASDAQ: INFI)
Over the last 12 months, Infinity Pharma has seen a steady climb and recent selloff. Wells Fargo recently upgraded the stock to Equal-Weight, and it was trading higher just prior press time.
Why is INFI Moving?
As mentioned, INFI is moving because the stock was upgraded by Wells Fargo. Moreover, Benzinga News reports that INFI is a popular upgrade stock. Infinity has topped its revenue estimates, recovered from a Q2 loss and recently released positive updates from its Phase 2 MARIO-275 Urothelial Cancer (UC) trial.
Where to Buy Infinity Pharmaceuticals Inc Stock
You can purchase INFI stock at any time using the brokers listed below. Benzinga reviews these brokers to ensure that they offer quality pricing and service.
Stay Ahead of the Game on INFI
Benzinga Pro is your one-stop shop for investment information, charts and real-time data. You can increase your net worth, invest in your future and make smart decisions with your stock portfolio.
Data for Infinity Pharmaceuticals as of July 28, 2021
Summary of Infinity Pharmaceuticals Inc as of July 28, 2021:
Price Change: $1.520 to $2.17
52 Week Low: $0.82
52 Week High: $5.98
Market Cap: $134.854M
P/E Ratio: -
Dividend Yield: -
Significant Dates for Infinity Pharmaceuticals Inc:
Next Earnings Date: July 27, 2021, EPS of -0.130
Last Earnings Date: May 13, 2021 EPS of $-0.150
Ex-Dividend Date: -
Dividend Payment Date: -
Technical Data of Infinity Pharmaceuticals Inc as of July 28, 2021:
RSI: 41.3803 ⮕ Bullish
MACD: Signal Line (0.1217) Over MACD (-0.1209) ⮕ Bullish
Bollinger Bands: Price ($2.17), 20-Day SMA ($2.9078), Lower Band ($2.3759), Upper Band ($3.7745) ⮕ Bullish
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.